Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   ARCHIVES OF CLINICAL INFECTIOUS DISEASES   JULY 2016 , Volume 11 , Number 3; Page(s) 0 To 0.
 
Paper: 

RESEARCH ARTICLE: SEROPREVALENCE OF TOXOPLASMA GONDII INFECTION IN PATIENTS WITH ALZHEIMER’S DISEASE

 
 
Author(s):  MENATI RASHNO MOHAMMAD, FALLAHI SHIRZAD*, KHEIRANDISH FARNAZ, BAGHERI SHAHROKH, KAYEDI MOHAMMAD HASSAN, BIRJANDI MEHDI
 
* DEPARTMENT OF MEDICAL PARASITOLOGY AND MYCOLOGY, SCHOOL OF MEDICINE, LORESTAN UNIVERSITY OF MEDICAL SCIENCES, KHORRAMABAD, I.R. IRAN
 
Abstract: 

Background: Toxoplasmosis is one of the most important diseases in humans and animals. Almost one-third of the human population around the world is infected with toxoplasmosis. The agent of this parasitic disease is a protozoan calledToxoplasma gondii (T.gondii) that causes encephalitis in people with suppressed immune systems and abortion, mental retardation and chorioretinitis in the fetus. Alzheimer’s disease (AD) is the most important neurodegenerative disease.
Objectives: Due to the high prevalence of toxoplasmosis in Iran and evidence on its impact on neurodegenerative diseases, this study was performed to evaluate theT. gondii infection in patients with AD.
Patients and Methods: In this case-control study, after selection of alzheimer’s patients (APs) referred to ImamReza psychiatric hospital of Khorramabad, west of Iran, and healthy controls (each group consisted of 87 individuals), using the convenience sampling method and under the supervision of a neurologist, blood samples were taken during July 2014 and January 2015. The collected samples were transferred to the research laboratory of parasitology under cold chain storage and then, the serum samples were separated by centrifugation and were frozen at -20°C until use. TheT. gondii IgM and IgG specific antibodies were assessed in serum samples using commercial Enzyme Linked Immunosorbent Assay (ELISA) kits.
Results: The overall prevalence of T. gondii infection in patients with AD and the control group, using ELISA assay, was obtained as 66.6% (58.87) and 56.32% (49.87), respectively (P=0.99). In this study, there was no significant association betweenT. gondii infection and AD. On the other hand, no statistically significant difference was observed between the two groups in terms of infection withT.
gondii (P=0.99).
Conclusions: Higher prevalence of T. gondii in patients with AD compared to controls showed the possible impact of this parasite in AD, which may exacerbate symptoms, and this requires special attention of specialists and patient families.

 
Keyword(s): SEROPREVALENCE, TOXOPLASMA GONDII, PATIENTS WITH ALZHEIMER’S DISEASE, CONTROL GROUP
 
 
References: 
  • Not Registered.
  •  
  •  
 
Citations: 
 
+ Click to Cite.
APA: Copy

MENATI RASHNO, M., & FALLAHI, S., & KHEIRANDISH, F., & BAGHERI, S., & KAYEDI, M., & BIRJANDI, M. (2016). RESEARCH ARTICLE: SEROPREVALENCE OF TOXOPLASMA GONDII INFECTION IN PATIENTS WITH ALZHEIMER’S DISEASE. ARCHIVES OF CLINICAL INFECTIOUS DISEASES, 11(3), 0-0. https://www.sid.ir/en/journal/ViewPaper.aspx?id=511185



Vancouver: Copy

MENATI RASHNO MOHAMMAD, FALLAHI SHIRZAD, KHEIRANDISH FARNAZ, BAGHERI SHAHROKH, KAYEDI MOHAMMAD HASSAN, BIRJANDI MEHDI. RESEARCH ARTICLE: SEROPREVALENCE OF TOXOPLASMA GONDII INFECTION IN PATIENTS WITH ALZHEIMER’S DISEASE. ARCHIVES OF CLINICAL INFECTIOUS DISEASES. 2016 [cited 2021July27];11(3):0-0. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=511185



IEEE: Copy

MENATI RASHNO, M., FALLAHI, S., KHEIRANDISH, F., BAGHERI, S., KAYEDI, M., BIRJANDI, M., 2016. RESEARCH ARTICLE: SEROPREVALENCE OF TOXOPLASMA GONDII INFECTION IN PATIENTS WITH ALZHEIMER’S DISEASE. ARCHIVES OF CLINICAL INFECTIOUS DISEASES, [online] 11(3), pp.0-0. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=511185.



 
  pdf-File
Yearly Visit 62
 
 
Latest on Blog
Enter SID Blog